Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLIS TechnologiesNZSE:BLT +12.50% Cash Ratio is 5.09 as of Mar. 2026, which is 36% above its 10-year median of 3.73. The stock has 8 warning signs investors should review. Among 1,382 Biotechnology companies, BLIS Technologies ranks better than 65.05% on this metric.
BLIS Technologies has a Cash Ratio of 5.09. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for BLIS Technologies's Cash Ratio or its related term are showing as below:
NZSE:BLT'
s Cash Ratio Range Over the Past 10 Years
Min: 0.61 Med: 3.73 Max: 6.97
Current: 5.09
During the past 13 years, BLIS Technologies's highest Cash Ratio was 6.97. The lowest was 0.61. And the median was 3.73.
NZSE:BLT's Cash Ratio is ranked better than 65.05% of 1382
companies
in the Biotechnology industry
Industry Median: 2.93
vs NZSE:BLT: 5.09
BLIS Technologies (NZSE:BLT) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
BLIS Technologies Cash Ratio Related Terms
BLIS Technologies Cash Ratio Historical Data
* Premium members only.
The historical data trend for BLIS Technologies's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:BLT vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, BLIS Technologies's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLIS Technologies Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLIS Technologies's Cash Ratio distribution charts can be found below:
* The bar in red indicates where BLIS Technologies's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLIS Technologies (NZSE:BLT) has a Cash Ratio of 5.09 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BLIS Technologies and its competitors. This is 36% above median its historical median of 3.73. Over the past decade, BLIS Technologies' Cash Ratio has ranged from 0.61 to 6.97. According to the industry distribution chart, BLIS Technologies ranks #483 out of 1382 companies in the Biotechnology industry, placing it in the top 34.9%.
Is BLIS Technologies' Cash Ratio too high?
BLIS Technologies' current Cash Ratio of 5.09 is 36% above median its 10-year median of 3.73. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 6.97. The Biotechnology industry median Cash Ratio is 2.93. BLIS Technologies' value of 5.09 is 73.7% above this industry median. Based on the distribution chart, BLIS Technologies ranks #483 out of 1382 companies in the Biotechnology industry, which is above the industry midpoint.
How does BLIS Technologies' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLIS Technologies ranks #483 out of 1382 companies for Cash Ratio. This puts BLIS Technologies in the upper half of its industry. The industry median Cash Ratio is 2.93. BLIS Technologies' value of 5.09 is 73.7% above this benchmark. Historically, BLIS Technologies' own Cash Ratio has ranged from 0.61 to 6.97 over the past decade. While the company's 10-year median is 3.73 vs. the industry median of 2.93, BLIS Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLIS Technologies's current Cash Ratio of 5.09 is 73.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BLIS Technologies and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLIS Technologies's current Cash Ratio is 5.09, which is 36% above median its own 10-year median of 3.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Significantly Overvalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.03 — trading 35% above its estimated fair value. The current Cash Ratio is 5.09, which is 36% above median its 10-year median of 3.73 and 73.7% above the Biotechnology industry median of 2.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current Cash Ratio is 5.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:BLT has been successfully added to your 
